Mecobon 2500 mcg Injection

Mecobon is a high-potency Methylcobalamin injection delivering 2500 mcg of the active, coenzyme form of Vitamin B12 directly into the body via intramuscular route. Unlike cyanocobalamin — the synthetic form used in most oral supplements — Methylcobalamin is the biologically active form that the nervous system can utilize immediately without requiring hepatic conversion.

With 50% of randomly selected young adult Indian vegans showing subnormal B12 levels (Harrison’s Principles of Internal Medicine, 17th Edition), and neuropathy rates rising across all demographics, Mecobon addresses one of the most underdiagnosed and undertreated deficiency conditions in India today.

Mechanism of Action

Methylcobalamin functions as a coenzyme in two critical biochemical pathways:

• Methionine Synthase Pathway: Converts homocysteine to methionine — directly reducing elevated homocysteine levels that are associated with cardiovascular dysfunction, arterial stiffness, and endothelial damage.
• Myelin Synthesis: Participates in the synthesis of myelin sheath — the protective coating around nerve fibers — making it essential for nerve regeneration and the reversal of neuropathic damage.

Key Therapeutic Actions

Stops Progression of Neuropathy-Induced Cerebral Dysfunction and Myopathy
Mecobon’s active Methylcobalamin halts the progression of neuropathic degeneration by restoring myelin integrity and supporting axonal regeneration in both peripheral and central nervous system pathways.

Treats Tingling, Pricking, Numbness and Muscle Weakness
These are the hallmark symptoms of peripheral neuropathy caused by B12 deficiency. Mecobon directly addresses the root neurological cause — not just the symptoms — providing meaningful clinical relief when administered consistently.

Checks Development of Cardiovascular Autonomic Neuropathy
Diabetic and age-related autonomic neuropathy affecting heart rate regulation and blood pressure control is a serious complication. Mecobon’s role in homocysteine reduction and nerve protection helps check the progression of autonomic cardiac neuropathy.

Reduces Homocysteine Levels
Elevated homocysteine is an independent risk factor for endothelial dysfunction and arterial stiffness. Mecobon reduces homocysteine via the methionine synthase pathway — improving vascular health outcomes in high-risk patients.

Benefits in Pregnancy and Maternal Health

• Improves the nutritional status of pregnant women with B12 deficiency
• Essential for normal growth and development of the foetus
• Critical for neural tube formation and brain development in the developing baby
• Supports megaloblastic anaemia management during pregnancy
• Safe in pregnancy and nursing mothers

Clinical Indications

• Peripheral neuropathy — diabetic, alcoholic, drug-induced
• Tingling, numbness, burning sensations in extremities
• Muscle weakness and myopathy associated with B12 deficiency
• Megaloblastic anaemia in pregnant and lactating women
• Cardiovascular autonomic neuropathy
• Elevated homocysteine levels with cardiovascular risk
• B12 deficiency in vegans, vegetarians, and elderly patients
• Post-surgical neurological recovery support

Recommended Dosage

For Megaloblastic Anaemia and Neuropathy:

• 1–2 injections per week given intramuscularly for 4 weeks
• Maintenance: 1 injection per month given intramuscularly for 3 months

Dosage to be administered as directed by a registered medical practitioner.

Why is it Better than Cyanocobalamin?

Most B12 products use cyanocobalamin — a synthetic, low-cost form that cannot be utilised by the body directly. It requires hepatic (liver) conversion before it becomes active, a process that is inefficient in elderly patients, those with liver conditions, and individuals with MTHFR gene variants who have a reduced capacity to process synthetic B12 forms.

This conversion also releases a small cyanide byproduct — an unnecessary and avoidable metabolic burden, particularly in renally compromised patients where cyanide clearance is already reduced.

Mecobon delivers Methylcobalamin in its already-active coenzyme form — bypassing hepatic conversion entirely. The advantages over cyanocobalamin are clinically meaningful:

• Immediately bioavailable — no conversion step required, 100% of the administered dose is active from the moment of injection
• Crosses the blood-brain barrier more effectively — essential for neurological conditions where central nervous system penetration determines therapeutic outcome
• Retained in tissues significantly longer — higher tissue retention means more sustained therapeutic effect between doses
• No cyanide byproduct — safe for patients with renal impairment where cyanide clearance may be compromised
• Effective in MTHFR gene variant patients — individuals who cannot efficiently process cyanocobalamin respond well to direct Methylcobalamin administration
• Superior for neuropathy and myelin regeneration — the active coenzyme form is directly utilized in myelin sheath synthesis, making it the clinically preferred form for neurological conditions

Cyanocobalamin may cost less to produce — but Mecobon delivers what matters: direct, complete, and immediate B12 activity where it is needed most. For patients with peripheral neuropathy, nerve degeneration, or homocysteine-related cardiovascular risk, the choice between Methylcobalamin and Cyanocobalamin is not a matter of preference — it is a matter of clinical efficacy.

Composition